Candriam S.C.A. Seagen Inc. Transaction History

Candriam S.C.A.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $85,987 - $97,055	449 Added 0.08%	530,228 $112 Million
Q2 2023 Aug 08, 2023	SELL	$187.64 - $206.25 $8.98 Million - $9.87 Million	-47,841 Reduced 8.28%	529,779 $102 Million
Q1 2023 May 12, 2023	SELL	$127.59 - $203.08 $29.4 Million - $46.8 Million	-230,252 Reduced 28.5%	577,620 $117 Million
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $7.96 Million - $9.44 Million	67,844 Added 9.17%	807,872 $104 Million
Q3 2022 Nov 10, 2022	SELL	$135.27 - $180.11 $5.14 Million - $6.85 Million	-38,017 Reduced 4.89%	740,028 $101 Million

Q2 2022 Aug 03, 2022	SELL	$108.81 - $179.33 $11.7 Million - $19.3 Million	-107,831 Reduced 12.17%	778,045 $138 Million
Q1 2022 May 13, 2022	SELL	$119.61 - $157.85 $331,439 - $437,402	-2,771 Reduced 0.31%	885,876 $128 Million
Q4 2021 Feb 10, 2022	BUY	$142.57 - $190.86 $373,961 - $500,625	2,623 Added 0.3%	888,647 $137 Million
Q3 2021 Nov 09, 2021	BUY	$142.45 - $169.82 $6.3 Million - $7.51 Million	44,207 Added 5.25%	886,024 $150 Million
Q2 2021 Jul 20, 2021	BUY	$135.08 - $161.1 $44.5 Million - $53 Million	329,160 Added 64.21%	841,817 $133 Million
Q1 2021 Apr 29, 2021	BUY	$137.51 - $190.8 $1,925 - $2,671	14 Added 0.0%	512,657 $86.2 Million
Q4 2020 Jan 22, 2021	BUY	$164.63 - $211.93 $84.4 Million - $109 Million	512,643 New	512,643 $89.8 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.